(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.47%) $27.23
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
1.08% $ 15.91
@ $19.52
Wydano: 14 vas. 2024 @ 21:28
Zwrot: -18.47%
Poprzedni sygnał: vas. 14 - 18:53
Poprzedni sygnał:
Zwrot: 2.55 %
Live Chart Being Loaded With Signals
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong...
Stats | |
---|---|
Dzisiejszy wolumen | 362 617 |
Średni wolumen | 639 958 |
Kapitalizacja rynkowa | 1.57B |
EPS | $0 ( 2024-02-27 ) |
Następna data zysków | ( $-0.930 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.55 |
ATR14 | $0.0180 (0.11%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-03 | Smiley Joshua L | Buy | 7 145 | American Depositary Shares |
2024-04-04 | Smiley Joshua L | Sell | 1 988 | American Depositary Shares |
2024-04-03 | Smiley Joshua L | Sell | 7 145 | Restricted Share Units |
2024-04-03 | Reinhart Harald | Buy | 5 270 | American Depositary Shares |
2024-04-04 | Reinhart Harald | Sell | 2 105 | American Depositary Shares |
INSIDER POWER |
---|
72.37 |
Last 100 transactions |
Buy: 2 027 943 | Sell: 363 897 |
Wolumen Korelacja
Zai Lab Ltd Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
MMAC | 0.88 |
NETE | 0.872 |
BOCH | 0.84 |
TFSL | 0.832 |
SHSP | 0.828 |
SNFCA | 0.824 |
LWAC | 0.815 |
DOOO | 0.809 |
CLGN | 0.804 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Zai Lab Ltd Korelacja - Waluta/Towar
Zai Lab Ltd Finanse
Annual | 2023 |
Przychody: | $266.72M |
Zysk brutto: | $170.90M (64.08 %) |
EPS: | $-3.46 |
FY | 2023 |
Przychody: | $266.72M |
Zysk brutto: | $170.90M (64.08 %) |
EPS: | $-3.46 |
FY | 2022 |
Przychody: | $215.04M |
Zysk brutto: | $141.02M (65.58 %) |
EPS: | $-5.03 |
FY | 2021 |
Przychody: | $144.31M |
Zysk brutto: | $92.07M (63.80 %) |
EPS: | $-9.07 |
Financial Reports:
No articles found.
Zai Lab Ltd
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej